GlassScriptPhysician profile
Keri Anne Squittieri
NPI 1366727497
$16,614.25
in general payments reported to CMS, 2019-2025
24 companies · $28.20 in 2025
The $28.20 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,314 · 2022: $2,846 · 2023: $1,904 · 2024: $11K · 2025: $28.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $1,849 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,522.20 |
| Food and Beverage | $1,849.23 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $11,206.29 | 2021-2024 | Ilumya |
| Abbvie INC. | $1,451.12 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $637.34 | 2022-2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $494.81 | 2021-2023 | |
| Almirall LLC | $484.09 | 2021-2023 | Klisyri |
| Galderma Laboratories, L.P. | $293.23 | 2021-2023 | Aklief, Epsolay, Twyneo |
| Genzyme Corporation | $278.54 | 2021-2023 | |
| Journey Medical Corporation | $249.29 | 2021-2022 | |
| Ucb, INC. | $220.09 | 2022-2023 | Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $211.16 | 2021-2023 | Jublia |
| Arcutis Biotherapeutics, INC. | $181.06 | 2023 | |
| Lilly USA, LLC | $166.83 | 2022-2023 | Taltz, Olumiant |
| Incyte Corporation | $146.81 | 2022 | |
| Dermavant Sciences, INC. | $139.20 | 2023 | Vtama |
| Janssen Biotech, INC. | $94.28 | 2022-2025 | Tremfya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $82.21 | 2022-2023 | |
| Vyne Pharmaceuticals INC. | $73.37 | 2021 | |
| Epi Health, LLC | $58.25 | 2021-2022 | |
| Leo Pharma INC. | $57.57 | 2021-2022 | |
| Amgen INC. | $26.46 | 2023 | Otezla |
| Mayne Pharma Commercial LLC | $19.49 | 2023 | |
| Sebela Pharmaceuticals INC. | $16.84 | 2023 | Naftin |
| Allergan, INC. | $13.40 | 2022 | |
| Mission Pharmacal Company | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Squittieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.